Synthesis and Anticancer Properties of Rare Earth Substituted Tungstophosphoric Polyoxometalate Containing 5-Fluorouracil

Three novel rare earth substituted polyoxometalates containing 5‐fluorouracil, K10C4H4FN2O2Pr(PW11O39)2·24H2O, K10C4H4FN2O2Nd(PW11O39)2·12H2O and K10C4H4FN2O2Sm(PW11O39)2·12.5H2O were synthesized and structurally characterized by elemental analysis, IR spectra, X‐ray powder diffraction and 183W NMR. The results indicate that the compounds have Keggin structure of heteropolyanion and ring structure of 5‐fluorouracil. The cytotoxicity test of the compounds in human renal embryonic cell HEK293 and the activity inhibiting human cervical carcinoma cell Hela were studied by the methyl thiazolyl tetrazolium method with 5‐fluorouracil for the positive control group. The toxicity of the compounds are lower than that of 5‐fluorouracil. K10C4H4FN2O2Pr(PW11O39)2·24H2O has no apparent toxicity in vitro and can inhibit Hela cells in vitro with significant difference compared with 5‐Fu. Three novel rare earth substituted polyoxometalates containing 5‐fluorouracil, K10C4H4FN2O2Pr(PW11O39)2·24H2O, K10C4H4FN2O2Nd(PW11O39)2·12H2O and K10C4H4FN2O2Sm(PW11O39)2·12.5H2O were synthesized. The toxicity of the compounds are lower than that of 5‐fluorouracil. And the compounds can inhibit Hela cell significantly.